Citation Impact
Citing Papers
A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
2007 StandoutNobel
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Emerging therapies for the treatment of hepatitis C
2013 StandoutNobel
Aromatase inhibitors ? mechanisms for non-steroidal inhibitors
1994
Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade
2008 Standout
Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy
2001 StandoutNobel
Targeting the dopamine D2receptor in schizophrenia
2006
Pharmacokinetics of finrozole (MPV‐2213ad), a novel selective aromatase inhibitor, in healthy men
2001
Levocabastine
1995
Methotrexate modulates the kinetics of adenosine in humans in vivo
2005
Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies
2016 StandoutNobel
Aromatase, Aromatase Inhibitors, and Breast Cancer
2001
Long-Acting Risperidone
2004
Modelling hepatitis C therapy—predicting effects of treatment
2015
Clinical Pharmacology of New Histamiine H1 Receptor Antagonists
1999
COVID-19: A promising cure for the global panic
2020 Standout
Anti–β1-adrenergic receptor antibodies and heart failure: causation, not just correlation
2004 StandoutNobel
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models
2010
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
2019 StandoutNobel
Medicinal mushroom modulators of molecular targets as cancer therapeutics
2005 Standout
Risperidone
2012
Replication Vesicles are Load- and Choke-Points in the Hepatitis C Virus Lifecycle
2013
Therapeutic potential of β-arrestin- and G protein-biased agonists
2010 StandoutNobel
Interferon-based therapy of hepatitis C
2007
Allergic Rhinitis and Its Impact on Asthma
2001 Standout
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
2008
White Button Mushroom Phytochemicals Inhibit Aromatase Activity and Breast Cancer Cell Proliferation
2001
Differential cardioprotective/cardiotoxic effects mediated by β-adrenergic receptor subtypes
2005 StandoutNobel
Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay
2001 Standout
Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study
2016
Expert opinion on the treatment of patients with chronic hepatitis C
2008
The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity
2017 StandoutNobel
Fish bioaccumulation and biomarkers in environmental risk assessment: a review
2002 Standout
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals
2009
Flavonoids: Promising anticancer agents
2003 Standout
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
2008 Standout
Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development
2007
Effects of steroidal and non steroidal aromatase inhibitors on sexual behavior and aromatase-immunoreactive cells and fibers in the quail brain
1994
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans
2008
Some effects of the fungicide propiconazole on cytochrome P450 and glutathione S-transferase in brown trout (Salmo trutta)
1999
Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
2011
Stereochemical comparison of nebivolol with other β‐blockers
2007
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
P450 inhibitors of use in medical treatment: Focus on mechanisms of action
1995
Antifungal agents: mechanisms of action
2003 Standout
Linkage of β1-adrenergic stimulation to apoptotic heart cell death through protein kinase A–independent activation of Ca2+/calmodulin kinase II
2003 StandoutNobel
Hepatitis C Virus
2013
A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry
2014 Standout
Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase.
2002 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Structure−Activity Relationships of a New Family of Steroidal Aromatase Inhibitors. 1. Synthesis and Evaluation of a Series of Analogs Related to 19-[(Methylthio)methyl]androstenedione (RU54115)
1996
Aromatase inhibitors as potential cancer chemopreventives.
1998
Asymmetric hydrogenation of alkyl(vinyl)thioethers: a promising approach to α-chiral thioethers
2007 StandoutNobel
Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 2: Exposure–response analyses for efficacy and safety variables
2014
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Aromatase Inhibitors in the Treatment of Breast Cancer
2005
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice
2002 StandoutNobel
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus
2019 StandoutNobel
β-Adrenergic Receptor Blockade in Chronic Heart Failure
2000
Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates
2014
A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry
2016 StandoutNobel
Linkage of β1-adrenergic stimulation to apoptotic heart cell death through protein kinase A–independent activation of Ca2+/calmodulin kinase II
2003 StandoutNobel
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
2013
Physiological Roles of Vascular Nucleoside Transporters
2007
Nebivolol
2006
A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes
2014 StandoutNobel
Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals
2013 StandoutNobel
Long-term Follow-up After Bariatric Surgery
2014
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Anti–β1-adrenergic receptor antibodies and heart failure: causation, not just correlation
2004 StandoutNobel
Efficacy and Safety of Levocabastine Nasal Spray for Seasonal Allergic Rhinitis
1999
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Towards a small animal model for hepatitis C
2009 StandoutNobel
Paliperidone for schizophrenia
2008
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
Biochemistry and pharmacology of 7α-substituted androstenediones as aromatase inhibitors
1997 StandoutNobel
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon‐alpha therapy via mathematical modeling
2014
Sustained virological response with intravenous silibinin: individualized IFN ‐free therapy via real‐time modelling of HCV kinetics
2014
Prescribed drugs containing nitrogen heterocycles: an overview
2020 Standout
Works of Eric Snoeck being referenced
Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients
2010
Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects
1997
New non-steroidal aromatase inhibitors: Focus on R76713
1990
A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2‐receptor antagonists cimetidine and ranitidine
1997
Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa‐2a (40KD) plus ribavirin
2006
Pharmacokinetics of ribavirin in patients with hepatitis C virus
2006
Vorozole, a specific non-steroidal aromatase inhibitor
1994
Plasma protein binding of risperidone and its distribution in blood
1994
Long-Term Results of a Prospective Study on Laparoscopic Adjustable Gastric Banding for Morbid Obesity
2010
R 75251, a new inhibitor of steroid biosynthesis
1990
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
2010
The Pharmacokinetic Properties of Topical Levocabastine
1995
Haemodynamic effects and pharmacokinetics of oral d -and l -nebivolol in hypertensive patients
1996
Clinical Pharmacokinetics of Nebivolol
1991
Physiological Red Blood Cell Kinetic Model to Explain the Apparent Discrepancy Between Adenosine Breakdown Inhibition and Nucleoside Transporter Occupancy of Draflazine
1998